Beyond Air (XAIR)


Market Price (11/18/2026): $1.81 | Market Cap: $3.0 MilSector: Health Care | Industry: Life Sciences Tools & Services

Beyond Air (XAIR)


Market Price (11/18/2026): $1.81
Market Cap: $3.0 Mil
Sector: Health Care
Industry: Life Sciences Tools & Services

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 61%

Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -82%

Megatrend and thematic drivers
Megatrends include Precision Medicine. Themes include Targeted Therapies, and Biopharmaceutical R&D.

Weak multi-year price returns
2Y Excs Rtn is -123%, 3Y Excs Rtn is -168%

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -28 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -365%

Debt is significant
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 19017%

Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 62%

Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -241%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -255%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -46206%

High stock price volatility
Vol 12M is 182%

Significant short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 208%

Key risks
XAIR key risks include [1] severe financial distress characterized by a high cash burn rate and expensive debt, Show more.

0 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 61%
1 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -82%
2 Megatrend and thematic drivers
Megatrends include Precision Medicine. Themes include Targeted Therapies, and Biopharmaceutical R&D.
3 Weak multi-year price returns
2Y Excs Rtn is -123%, 3Y Excs Rtn is -168%
4 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -28 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -365%
5 Debt is significant
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 19017%
6 Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 62%
7 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -241%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -255%
8 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -46206%
9 High stock price volatility
Vol 12M is 182%
10 Significant short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 208%
11 Key risks
XAIR key risks include [1] severe financial distress characterized by a high cash burn rate and expensive debt, Show more.

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/17/2026

Nov 16: down 5.2% in one day (S&P 500 down 1.9%)
The stock moved without company news. The broader market also declined, with Nvidia tugging the market lower again and chip stocks falling.

Up 25.8% from its Oct 23 low to Nov 11, down 23.6% since (S&P 500 down 0.0%)
The stock saw an overall increase without company-specific news driving the sustained upward movement. Its largest daily gain occurred on Nov 10, and it also rose on Nov 9 amidst a broad-based market rally.

Oct 8: down 9.1% on its earnings report (S&P 500 down 0.4%)
The stock declined following Beyond Air's October 8 preannouncement of preliminary revenue for the quarter ended September 30, 2026. The company stated this $2.3 million figure represented the highest quarterly revenue reported.

Show more
Prices as of 11/17/2026

Nov 16: down 5.2% in one day (S&P 500 down 1.9%)
The stock moved without company news. The broader market also declined, with Nvidia tugging the market lower again and chip stocks falling.

Up 25.8% from its Oct 23 low to Nov 11, down 23.6% since (S&P 500 down 0.0%)
The stock saw an overall increase without company-specific news driving the sustained upward movement. Its largest daily gain occurred on Nov 10, and it also rose on Nov 9 amidst a broad-based market rally.

Oct 8: down 9.1% on its earnings report (S&P 500 down 0.4%)
The stock declined following Beyond Air's October 8 preannouncement of preliminary revenue for the quarter ended September 30, 2026. The company stated this $2.3 million figure represented the highest quarterly revenue reported.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -61.9% change in XAIR stock from 7/31/2026 to 11/17/2026 was primarily driven by a -97.7% change in the company's P/S Multiple.
(LTM values as of)731202611172026Change
Stock Price ($)5.282.01-61.9%
Change Contribution By: 
Total Revenues ($ Mil)880.1%
P/S Multiple0.40.0-97.7%
Shares Outstanding (Mil)101534.9%
Cumulative Contribution-61.9%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/17/2026
ReturnCorrelation
XAIR-61.9% 
Market (SPY)-1.7%35.5%
Sector (XLV)14.4%2.8%

Fundamental Drivers

The -80.9% change in XAIR stock from 4/30/2026 to 11/17/2026 was primarily driven by a -98.6% change in the company's P/S Multiple.
(LTM values as of)430202611172026Change
Stock Price ($)10.502.01-80.9%
Change Contribution By: 
Total Revenues ($ Mil)7811.0%
P/S Multiple0.70.0-98.6%
Shares Outstanding (Mil)001094.6%
Cumulative Contribution-80.9%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/17/2026
ReturnCorrelation
XAIR-80.9% 
Market (SPY)2.4%16.1%
Sector (XLV)27.9%7.8%

Fundamental Drivers

The -95.1% change in XAIR stock from 10/31/2025 to 11/17/2026 was primarily driven by a -91.3% change in the company's P/S Multiple.
(LTM values as of)1031202511172026Change
Stock Price ($)41.202.01-95.1%
Change Contribution By: 
Total Revenues ($ Mil)5860.7%
P/S Multiple0.10.0-91.3%
Shares Outstanding (Mil)00-65.2%
Cumulative Contribution-95.1%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/17/2026
ReturnCorrelation
XAIR-95.1% 
Market (SPY)8.5%5.7%
Sector (XLV)30.6%4.0%

Fundamental Drivers

The -99.8% change in XAIR stock from 10/31/2023 to 11/17/2026 was primarily driven by a -100.0% change in the company's P/S Multiple.
(LTM values as of)1031202311172026Change
Stock Price ($)932.002.01-99.8%
Change Contribution By: 
Total Revenues ($ Mil)0812928.8%
P/S Multiple1,239.40.0-100.0%
Shares Outstanding (Mil)00117.5%
Cumulative Contribution-99.8%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2023 to 11/17/2026
ReturnCorrelation
XAIR-99.8% 
Market (SPY)81.6%9.4%
Sector (XLV)56.4%2.9%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
XAIR Return79%-31%-70%-82%-90%-86%-100%
Peers Return14%-10%-18%21%-16%-0%-15%
S&P 500 Return27%-19%24%23%16%8%97%

Monthly Win Rates [3]
XAIR Win Rate67%42%33%33%25%9% 
Peers Win Rate55%47%52%53%45%55% 
S&P 500 Win Rate75%42%67%75%67%36% 

Max Drawdowns [4]
XAIR Max Drawdown-46%-52%-81%-86%-92%-95% 
Peers Max Drawdown-29%-34%-43%-28%-38%-30% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: LIN, APD, RMD, INSP, INGN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/17/2026 (YTD)

How Low Can It Go

EventXAIRS&P 500
2025 US Tariff Shock
  % Loss-53.1%-18.8%
  % Gain to Breakeven113.3%23.1%
  Time to Breakeven383 days79 days
2024 Yen Carry Trade Unwind
  % Loss-37.1%-7.8%
  % Gain to Breakeven59.0%8.5%
  Time to Breakeven103 days18 days
2022 Inflation Shock & Fed Tightening
  % Loss-48.0%-24.5%
  % Gain to Breakeven92.1%32.4%
  Time to Breakeven56 days427 days
2020 COVID-19 Crash
  % Loss-32.1%-33.7%
  % Gain to Breakeven47.2%50.9%
  Time to Breakeven5 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-28.3%-19.2%
  % Gain to Breakeven39.4%23.8%
  Time to Breakeven45 days105 days

Compare to LIN, APD, RMD, INSP, INGN

In The Past

Beyond Air's stock fell -53.1% during the 2025 US Tariff Shock. Such a loss loss requires a 113.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventXAIRS&P 500
2025 US Tariff Shock
  % Loss-53.1%-18.8%
  % Gain to Breakeven113.3%23.1%
  Time to Breakeven383 days79 days
2024 Yen Carry Trade Unwind
  % Loss-37.1%-7.8%
  % Gain to Breakeven59.0%8.5%
  Time to Breakeven103 days18 days
2022 Inflation Shock & Fed Tightening
  % Loss-48.0%-24.5%
  % Gain to Breakeven92.1%32.4%
  Time to Breakeven56 days427 days
2020 COVID-19 Crash
  % Loss-32.1%-33.7%
  % Gain to Breakeven47.2%50.9%
  Time to Breakeven5 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-28.3%-19.2%
  % Gain to Breakeven39.4%23.8%
  Time to Breakeven45 days105 days

Compare to LIN, APD, RMD, INSP, INGN

In The Past

Beyond Air's stock fell -53.1% during the 2025 US Tariff Shock. Such a loss loss requires a 113.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Beyond Air (XAIR)

```html

Beyond Air (XAIR) is a clinical-stage medical device and biopharmaceutical company focused on developing advanced nitric oxide (NO) generator and delivery systems. The company's core mission is to harness the therapeutic potential of nitric oxide for a range of medical conditions, positioning itself as an innovator in the intersection of medical technology and drug development.

The company's primary product is the LungFit system, a proprietary device engineered to generate and deliver precise doses of nitric oxide directly to patients. This system is currently undergoing clinical trials for several significant indications. These include the treatment of persistent pulmonary hypertension of the newborn (PPHN), acute viral pneumonia (such as COVID-19 and bronchiolitis), and lung infections caused by nontuberculous mycobacteria.

Beyond Air primarily targets patient populations within the medical and clinical fields, seeking to address conditions where inhaled nitric oxide therapy can offer new or improved treatment options. The company is also exploring its technology for solid tumors. As a clinical-stage company, its current focus is on advancing the LungFit system through clinical development, aiming to make these therapies available to healthcare providers and patients across its operational regions, which include Israel, Ireland, Australia, and the European Union.

```

AI Analysis | Feedback

Here are 1-3 brief analogies for Beyond Air (XAIR):

  • Like Inogen, but for therapeutic nitric oxide instead of oxygen.
  • Like Moderna, but focused on a nitric oxide generation and delivery platform for various medical treatments, instead of mRNA.

AI Analysis | Feedback

  • LungFit system: A nitric oxide (NO) generator and delivery system currently in clinical trials for treating conditions such as persistent pulmonary hypertension of the newborn, acute viral pneumonia, bronchiolitis, nontuberculous mycobacteria lung infections, and solid tumors.

AI Analysis | Feedback

Beyond Air, Inc. (XAIR) is a clinical-stage medical device and biopharmaceutical company. Its primary product, the LungFit system, is currently in clinical trials for various medical conditions.

As a clinical-stage company, Beyond Air, Inc. does not yet have commercialized products available for sale. Therefore, it does not currently have major customers, either companies or individuals, purchasing its products to generate revenue.

The company's current activities are focused on research, development, and conducting clinical trials, rather than commercial sales.

AI Analysis | Feedback

null

AI Analysis | Feedback

Management Team

Steve Lisi, Chief Executive Officer and Board Director
Mr. Lisi has served on Beyond Air's Board since January 2017 and as CEO since June 2017. Previously, he was Senior Vice President of Business and Corporate Development at Avadel Pharmaceuticals (AVDL), where he was instrumental in restructuring the company, raising over $125 million, and transforming it from a $100 million enterprise value to $1 billion in three years. Prior to Avadel, Mr. Lisi spent 18 years investing in the global healthcare industry at firms such as Deerfield Management, Millennium Management, and SAC Capital. He is also the Chairman of the Board of Beyond Cancer, an immuno-oncology company focused on solid tumors.

Dan Moorhead, Chief Financial Officer
Mr. Moorhead was appointed Chief Financial Officer, effective January 5, 2026. He brings over 20 years of finance leadership experience across public and private companies. Prior to joining Beyond Air, Mr. Moorhead served as Chief Financial Officer of Zynex, Inc., a publicly traded medical device company, from June 2017 to August 2025. Before his time at Zynex, he spent ten years at Evolving Systems, Inc., where he eventually became CFO. Mr. Moorhead is a CPA and holds a B.B.A. in Accounting from the University of Northern Colorado.

Michael Gaul, Chief Operating Officer
Mr. Gaul serves as the Chief Operating Officer of Beyond Air.

Frederick Montgomery, PhD, Vice President, Medical Systems
Dr. Montgomery is the Vice President, Medical Systems at Beyond Air.

John Jett, PhD, Head of Research and Clinical Development
Dr. Jett serves as the Head of Research and Clinical Development for Beyond Air.

AI Analysis | Feedback

The key risks to Beyond Air's business include its significant financial challenges and cash burn, the complexities of market adoption and intense competition, and the inherent uncertainties and potential delays in regulatory approvals for its products.

Key Risks to Beyond Air (XAIR)

  1. Financial Challenges and Cash Burn: Beyond Air faces significant financial hurdles, including substantial cash burn and recurring net losses. The company has burned through approximately $56 million in fiscal year 2024 and reported a net loss of $46.6 million in FY2025. This heavy cash consumption raises concerns about its ability to fund ongoing operations, product development, and commercialization efforts. Despite capital raises aimed at extending its cash runway, the company's financial health remains highly dependent on external funding and successful market penetration to achieve cash flow breakeven.
  2. Market Adoption and Competitive Pressures: The success of Beyond Air's LungFit system hinges on its acceptance by healthcare providers and its ability to compete effectively in a market dominated by established players. Mallinckrodt, for example, holds a significant market share (70%) in the nitric oxide delivery systems market. Beyond Air faces challenges in convincing customers to switch to its innovative system, and slow hospital onboarding can constrain revenue growth. This competitive landscape and the need for broad market adoption pose substantial risks to the company's commercial success.
  3. Regulatory Delays and Approval Uncertainties: As a medical device and biopharmaceutical company, Beyond Air's progress is highly dependent on obtaining and maintaining regulatory approvals for its products. Any setbacks, delays, or challenges in securing FDA approvals for next-generation LungFit systems or label expansions for new indications, as well as obtaining CE marking in Europe, could significantly delay market entry and impact revenue projections. The regulatory environment is complex and plays a crucial role in the company's future.

AI Analysis | Feedback

null

AI Analysis | Feedback

Addressable Markets for Beyond Air (XAIR) Products and Services

  • LungFit system for Persistent Pulmonary Hypertension of the Newborn (PPHN): The global addressable market for PPHN is estimated to be a $700 million opportunity.
  • LungFit system for Acute Viral Pneumonia (including COVID-19): The global acute respiratory infection market, which encompasses acute viral pneumonia, was valued at approximately USD 17.8 billion in 2023 and is projected to grow to around USD 20.3 billion by 2032.
  • LungFit system for Bronchiolitis: The global bronchiolitis drugs market was valued at USD 58.62 million in 2021 and is expected to reach USD 83.37 million by 2029.
  • LungFit system for Nontuberculous Mycobacteria (NTM) Lung Infections: The global nontuberculous mycobacterium treatment market size was valued at USD 9.8 billion in 2025 and is projected to reach USD 12.8 billion by the end of 2035. The NTM market across the seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) is forecast to grow from $2.0 billion in 2023 to $4.6 billion in 2033.
  • LungFit system for Solid Tumors: The global solid tumors market size was valued at USD 362.21 billion in 2024 and is projected to reach USD 1557.42 billion by 2032.

AI Analysis | Feedback

Expected Drivers of Future Revenue Growth for Beyond Air (XAIR)

Beyond Air (NASDAQ: XAIR) is anticipated to drive future revenue growth over the next 2-3 years through several key initiatives focused on its LungFit system.

  1. Increased Adoption and Commercialization of LungFit PH System: Beyond Air expects continued revenue growth from the increasing adoption and commercialization of its LungFit PH system. The company has reported sequential revenue growth and a significant increase in hospital clients, driven by enhanced marketing and customer education programs. An upgraded LungFit PH system, including a key software update, is also expected to meet accelerating demand.
  2. FDA Approval and Launch of the Next-Generation LungFit PH II System: The anticipated FDA approval of the second-generation LungFit PH II system is a significant driver. This new system is designed to be smaller, lighter, and fully transport-ready, addressing a primary limitation of the first-generation device. This improvement is expected to open up the entire nitric oxide (NO) market and boost the company's market presence upon its expected approval by year-end (calendar year 2026).
  3. Expansion of LungFit PH Label to Include Cardiac Surgery: Beyond Air has submitted a PMA supplement to the FDA for the expansion of the LungFit PH label to include cardiac surgery. The acceptance and substantive review of this supplement are expected to positively impact revenues, broadening the addressable market for the LungFit PH system. This impact is anticipated in the latter half of fiscal year 2025 and beyond.
  4. International Expansion of LungFit PH: The company is actively pursuing international expansion for its LungFit PH system. Beyond Air is expanding its global footprint with partnerships in 40 countries and aims to generate revenue in 12 countries by the end of calendar year 2026. Recent distribution agreements include key markets such as Germany, Brazil, Austria, the Netherlands, and Sri Lanka.

AI Analysis | Feedback

Share Issuance

  • In January 2026, Beyond Air entered a private placement to sell 3,930,818 shares of common stock (or pre-funded warrants) and warrants for approximately $5.0 million in gross proceeds.
  • In November 2025, the company secured an Equity Line of Credit (ELOC) agreement with Streeterville Capital, allowing them to sell up to $20 million of newly issued common stock over a 24-month period.
  • In July 2025, Beyond Air implemented a 1-for-20 reverse stock split to raise its per-share bid price above $1.00 and regain compliance with Nasdaq listing rules.

Inbound Investments

  • In November 2025, Beyond Air issued a $12.0 million promissory note to Streeterville Capital, bearing a 15% annual interest rate.
  • In January 2026, Beyond Air announced a binding agreement to sell 85% of its NeuroNOS subsidiary to XTL Biopharmaceuticals Ltd., expecting to receive $1 million in cash and up to $31.5 million in milestone-based contingent payments.
  • Subsequent to December 31, 2025, the company completed an additional $4.5 million equity financing.

Capital Expenditures

  • Capital expenditures were reported as -$1.98 million in the last 12 months.
  • Investing cash flow (capital expenditures) was reported as ($2.48 million) over the last twelve months.
  • The primary focus of capital expenditures is on the development and commercialization of its LungFit PH system, including the anticipated launch of its second-generation LungFit PH prior to the end of calendar 2026.

Better Bets vs. Beyond Air (XAIR)

Peer Outperformance in Life Sciences Tools & Services

XAIR has trailed 94% of its 109 Life Sciences Tools & Services peers over 5Y. Life Sciences Tools & Services ranks 8th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Life Sciences Tools & Services constituents that XAIR has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
13%
of 125 industry peers · -92.5% return
3Y
7%
of 115 industry peers · -99.7% return
5Y
6%
of 109 industry peers · -100.0% return
No Life Sciences Tools & Services peer with a comparable growth profile has beaten XAIR by more than 20pp over 5Y.
Median price return by industry across the Health Care sector, ranked by 5Y. Life Sciences Tools & Services is XAIR's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Health Care Distributors 5 16.4%84.2%198.3% CAH 522% · MCK 400% · COR 198%
Health Care Services 20 31.2%20.2%12.4% RDNT 150% · HIMS 116% · DGX 91%
Managed Health Care 8 76.8%-0.8%0.8% OSCR 155% · HQY 56% · ELV 9%
Health Care Facilities 26 17.8%19.4%-9.2% THC 258% · NHC 231% · EHC 186%
Health Care Equipment 49 -1.7%4.4%-20.2% GKOS 390% · UFPT 359% · TMDX 293%
Health Care Supplies 11 24.0%1.1%-40.5% LNTH 248% · HAE 108% · MMSI 25%
Pharmaceuticals 60 -18.7%1.7%-45.2% LQDA 1123% · KNSA 638% · XERS 586%
Life Sciences Tools & Services ← 110 -22.4%-26.1%-76.2% AXGN 400% · MEDP 187% · NTRA 156%
Health Care Technology 23 -23.5%-59.7%-83.4% VEEV -8% · DOCS -55%
Biotechnology 370 -33.7%-38.5%-83.9% ELVN 1378% · TRVI 1175% · DNTH 1141%
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.

Latest Trefis Analyses

Title
0ARTICLES

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

XAIRLINAPDRMDINSPINGNMedian
NameBeyond A.Linde Air Prod.ResMed Inspire .Inogen  
Mkt Price1.81513.87306.88238.6259.435.13149.03
Mkt Cap0.0236.768.434.11.70.117.9
Rev LTM836,23812,6025,7338813793,307
Op Inc LTM-289,8133,1311,89916-31957
FCF LTM-205,080-3011,58898-2139
FCF 3Y Avg-375,033-2,4741,56478-2029
CFO LTM-1910,7104,5711,771135-9953
CFO 3Y Avg-3310,0603,7391,698116-6907

Growth & Margins

XAIRLINAPDRMDINSPINGNMedian
NameBeyond A.Linde Air Prod.ResMed Inspire .Inogen  
Rev Chg LTM60.7%8.2%4.5%9.0%-0.2%13.7%8.6%
Rev Chg 3Y Avg1,050.3%3.8%-0.9%9.4%16.4%5.1%7.3%
Rev Chg Q0.5%9.2%4.6%5.9%-7.9%-2.4%2.5%
QoQ Delta Rev Chg LTM0.1%2.2%1.1%1.4%-2.0%-0.5%0.6%
Op Inc Chg LTM27.3%7.9%7.0%8.9%-57.1%-2.0%7.4%
Op Inc Chg 3Y Avg18.8%8.1%5.1%17.9%80.7%11.8%14.9%
Op Mgn LTM-364.8%27.1%24.8%33.1%1.8%-8.2%13.3%
Op Mgn 3Y Avg-1,525.5%26.6%24.2%32.4%2.6%-11.8%13.4%
QoQ Delta Op Mgn LTM13.5%-0.0%0.0%-0.4%-4.2%0.1%0.0%
CFO/Rev LTM-241.5%29.6%36.3%30.9%15.3%-2.4%22.4%
CFO/Rev 3Y Avg-1,224.3%29.4%30.4%32.2%13.6%-1.6%21.5%
FCF/Rev LTM-255.0%14.0%-2.4%27.7%11.1%-5.5%4.4%
FCF/Rev 3Y Avg-1,395.1%14.7%-20.5%29.7%9.1%-5.7%1.7%

Valuation

XAIRLINAPDRMDINSPINGNMedian
NameBeyond A.Linde Air Prod.ResMed Inspire .Inogen  
Mkt Cap0.0236.768.434.11.70.117.9
P/S0.06.55.46.02.00.43.7
P/Op Inc-0.024.121.818.0109.1-4.319.9
P/EBIT-0.024.7491.517.156.1-4.320.9
P/E-0.033.8-1,445.521.417.1-3.88.5
P/CFO-0.022.115.019.312.7-14.813.8
Total Yield-46,201.9%4.2%2.3%5.7%5.9%-23.6%3.2%
Dividend Yield0.0%1.2%2.3%1.0%0.0%0.0%0.5%
FCF Yield 3Y Avg-69,909.8%2.3%-4.0%4.4%3.3%-10.7%-0.8%
D/E361.50.10.30.00.00.10.1
Net D/E211.20.10.3-0.0-0.2-0.60.0

Returns

XAIRLINAPDRMDINSPINGNMedian
NameBeyond A.Linde Air Prod.ResMed Inspire .Inogen  
1M Rtn-16.2%3.1%2.4%0.1%-13.6%-17.9%-6.7%
3M Rtn-68.4%7.7%1.9%9.1%3.6%-8.4%2.7%
6M Rtn-79.0%2.2%6.5%15.5%39.7%-20.5%4.4%
12M Rtn-93.2%24.6%24.5%-1.4%-30.0%-23.5%-12.5%
3Y Rtn-99.7%30.9%22.9%64.9%-57.6%-10.6%6.1%
1M Excs Rtn-12.0%5.6%6.3%3.4%-11.7%-18.5%-4.2%
3M Excs Rtn-61.9%10.9%5.6%7.8%0.1%-6.3%2.9%
6M Excs Rtn-79.8%1.3%5.7%14.6%38.9%-21.2%3.5%
12M Excs Rtn-102.6%12.9%11.3%-11.5%-41.3%-34.8%-23.1%
3Y Excs Rtn-161.0%-34.3%-43.0%2.9%-120.7%-55.6%-49.3%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320212020
Beyond Air410  
Beyond Cancer000  
NeuroNos00   
License revenue   11
Total41011


Operating Income by Segment
$ Mil20252024
NeuroNos-00
Beyond Cancer-9-21
Beyond Air-35-42
Total-45-63


Net Income by Segment
$ Mil2025202420232022
NeuroNos-00  
Beyond Cancer-9-20-18-5
Beyond Air-39-44-41-39
Total-48-64-59-44


Assets by Segment
$ Mil20252024202320222021
Beyond Air25454871 
Beyond Cancer3122128 
NeuroNos20   
License revenue    41
Total3057699941


Price Behavior

Price Behavior
Market Price$2.01 
Market Cap ($ Bil)0.0 
First Trading Date03/16/2018 
Distance from 52W High-95.4% 
   50 Days200 Days
DMA Price$2.54$8.78
DMA Trenddowndown
Distance from DMA-20.9%-77.1%
 3M1YR
Volatility96.4%181.8%
Downside Capture561.10235.31
Upside Capture185.28-92.66
Correlation (S&P 500)36.9%5.9%
XAIR Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta2.402.393.64-3.85-1.730.18
Up Beta-14.26-2.322.57-0.031.700.88
Down Beta0.163.841.6052.5028.347.16
Up Capture260%65%250%-41%-55%-6%
Bmk +ve Days12182862130427
Stock +ve Days915224792314
Down Capture454%393%466%-1497%-586%83%
Bmk -ve Days10253664121325
Stock -ve Days13274176153410

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with XAIR
XAIR-92.8%181.8%-0.85-
Sector ETF (XLV)24.2%16.9%1.105.2%
Equity (SPY)10.2%13.8%0.455.4%
Gold (GLD)-6.3%28.8%-0.234.7%
Commodities (DBC)31.6%21.3%1.18-6.5%
Real Estate (VNQ)10.0%14.2%0.427.5%
Bitcoin (BTCUSD)-31.4%43.7%-0.7514.8%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with XAIR
XAIR-78.5%123.6%-0.74-
Sector ETF (XLV)8.6%15.4%0.368.8%
Equity (SPY)10.9%17.3%0.4613.8%
Gold (GLD)15.5%19.2%0.655.8%
Commodities (DBC)7.1%19.6%0.25-0.2%
Real Estate (VNQ)0.9%19.0%-0.0612.3%
Bitcoin (BTCUSD)-0.6%51.4%0.1716.6%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with XAIR
XAIR-68.9%1,321.0%0.63-
Sector ETF (XLV)12.4%16.8%0.613.2%
Equity (SPY)14.9%18.0%0.703.4%
Gold (GLD)11.2%16.6%0.550.8%
Commodities (DBC)7.4%18.2%0.320.4%
Real Estate (VNQ)5.8%20.7%0.242.4%
Bitcoin (BTCUSD)57.2%66.3%0.97-1.2%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity0.1 Mil
Short Interest: % Change Since 1015202625.8%
Average Daily Volume0.0 Mil
Days-to-Cover Short Interest4.8 days
Basic Shares Quantity0.0 Mil
Short % of Basic Shares208.1%

Earnings Returns History

Updated 11/10/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
10/8/2026-2.6%-4.3%-6.5%
8/18/2026-9.1%-13.1%-46.2%
6/26/2026-6.1%1,673.7%1,003.0%
2/13/20262.9%-1.0%-18.6%
11/14/2025-3.5%-14.0%-35.9%
8/18/20253.4%-3.0%4.3%
6/18/2025-29.0%-38.7%-41.8%
2/14/20254.7%-5.7%-18.8%
...
SUMMARY STATS   
# Positive1198
# Negative121415
Median Positive4.7%7.7%15.1%
Median Negative-4.8%-7.1%-18.6%
Max Positive10.9%1,673.7%1,003.0%
Max Negative-29.0%-38.7%-46.2%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
10/8/2026-2.6%-4.3%-6.5%
8/18/2026-9.1%-13.1%-46.2%
6/26/2026-6.1%1,673.7%1,003.0%
2/13/20262.9%-1.0%-18.6%
11/14/2025-3.5%-14.0%-35.9%
8/18/20253.4%-3.0%4.3%
6/18/2025-29.0%-38.7%-41.8%
2/14/20254.7%-5.7%-18.8%
11/18/20241.5%7.7%-9.3%
8/9/20242.0%12.1%-7.1%
2/16/2024-5.4%-14.6%-21.0%
11/17/2023-4.8%1.6%5.4%
8/15/2023-8.7%-22.7%-12.9%
6/23/2023-2.6%-8.0%-24.6%
2/13/20239.8%-0.5%10.9%
11/14/2022-4.8%-6.3%4.7%
8/15/20225.0%-9.9%-10.8%
6/30/202210.9%63.8%33.8%
2/14/20226.5%-1.7%-11.3%
11/15/20219.9%1.1%-31.0%
8/11/2021-3.1%4.2%28.8%
6/16/20210.6%14.5%19.2%
2/11/2021-2.6%4.7%-3.9%
SUMMARY STATS   
# Positive1198
# Negative121415
Median Positive4.7%7.7%15.1%
Median Negative-4.8%-7.1%-18.6%
Max Positive10.9%1,673.7%1,003.0%
Max Negative-29.0%-38.7%-46.2%

SEC Filings

Expand for More
Report DateFiling DateFiling
06/30/202608/13/202610-Q
03/31/202606/26/202610-K
12/31/202502/13/202610-Q
09/30/202511/10/202510-Q
06/30/202508/12/202510-Q
03/31/202506/20/202510-K
12/31/202402/10/202510-Q
09/30/202411/12/202410-Q
06/30/202408/06/202410-Q
03/31/202406/24/202410-K
12/31/202302/12/202410-Q
09/30/202311/13/202310-Q
06/30/202308/10/202310-Q
03/31/202306/22/202310-K
12/31/202202/10/202310-Q
09/30/202211/08/202210-Q
Collapse to Preview
Report DateFiling DateFiling
06/30/202608/13/202610-Q
03/31/202606/26/202610-K
12/31/202502/13/202610-Q
09/30/202511/10/202510-Q
06/30/202508/12/202510-Q
03/31/202506/20/202510-K
12/31/202402/10/202510-Q
09/30/202411/12/202410-Q
06/30/202408/06/202410-Q
03/31/202406/24/202410-K
12/31/202302/12/202410-Q
09/30/202311/13/202310-Q
06/30/202308/10/202310-Q
03/31/202306/22/202310-K
12/31/202202/10/202310-Q
09/30/202211/08/202210-Q
06/30/202208/11/202210-Q
03/31/202206/29/202210-K
12/31/202102/10/202210-Q
09/30/202111/12/202110-Q
06/30/202108/10/202110-Q
03/31/202106/10/202110-K
12/31/202002/09/202110-Q
09/30/202011/12/202010-Q
06/30/202008/06/202010-Q
03/31/202006/23/202010-K
12/31/201902/07/202010-Q
09/30/201911/06/201910-Q

Recent Forward Guidance

Updated 11/2/2026

Latest: Q3 2026 Earnings Reported 10/8/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 RevenueReported 8.00 Mil 0 AffirmedGuidance: 8.00 Mil for 2026
2027 RevenueReported16.00 Mil17.00 Mil18.00 Mil0 AffirmedGuidance: 17.00 Mil for 2027


Prior: Q2 2026 Earnings Reported 8/18/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 RevenueReported 8.00 Mil 0 AffirmedGuidance: 8.00 Mil for 2026
2027 RevenueReported16.00 Mil17.00 Mil18.00 Mil0 AffirmedGuidance: 17.00 Mil for 2027

Q4 2026 Earnings Reported 6/26/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 RevenueReported 8.00 Mil -11.1% LoweredGuidance: 9.00 Mil for 2026
2027 RevenueReported16.00 Mil17.00 Mil18.00 Mil   

Q3 2026 Earnings Reported 2/13/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 NeuroNOS Transaction ProceedsReported 32.50 Mil    
2026 RevenueReported8.00 Mil9.00 Mil10.00 Mil0 AffirmedGuidance: 9.00 Mil for 2026

Insider Activity

Updated 10/14/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Lin, Yi-Chien DirectBuy101420262.212,6075,761327,080Form
2Lin, Yi-Chien DirectBuy100220262.8015,39343,100407,100Form
3Lin, Yi-Chien DirectBuy100220262.712,0005,420352,300Form
4Lin, Yi-Chien DirectBuy100220262.693,0008,070344,320Form
5Goodman, Robert ScottChief Executive OfficerDirectBuy73120265.7634,722199,999200,575Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Lin, Yi-Chien DirectBuy101420262.212,6075,761327,080Form
2Lin, Yi-Chien DirectBuy100220262.8015,39343,100407,100Form
3Lin, Yi-Chien DirectBuy100220262.712,0005,420352,300Form
4Lin, Yi-Chien DirectBuy100220262.693,0008,070344,320Form
5Goodman, Robert ScottChief Executive OfficerDirectBuy73120265.7634,722199,999200,575Form
6Moorhead, Daniel JChief Financial OfficerDirectBuy73120265.764,34024,99824,998Form
Core Cache Last Updated: 11/17/2026